U.S. markets closed

Oncternal Therapeutics, Inc. (ONCT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4310+0.0856 (+24.78%)
At close: 04:00PM EST
0.4402 +0.01 (+2.13%)
After hours: 07:54PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.3454
Bid0.3800 x 800
Ask0.4190 x 1400
Day's Range0.3500 - 0.4450
52 Week Range0.2600 - 1.3300
Avg. Volume157,582
Market Cap25.416M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-0.7200
Earnings DateMar 07, 2024 - Mar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ONCT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Oncternal Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • Insider Monkey

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript

    Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […]

  • GlobeNewswire

    Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

    The first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitorsAdditional patients were treated in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients that have failed prior CD19 CAR

  • GlobeNewswire

    Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

    SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s third quarter financial results. The li